Alcon AG vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Alcon AG trades at $73.63 (market cap $36.44B), while YieldMax TSLA Option Income Strategy ETF trades at $21.59. The key difference: Alcon AG pays a 0.48% dividend while YieldMax TSLA Option Income Strategy ETF pays none, and Alcon AG is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| ALC | TSLY | |
|---|---|---|
Market Cap | $36.44B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $90.12 | $48.25 |
52-Week Low | $62.02 | $20.49 |
Enterprise Value | $40.28B | — |
Dividend Yield | 0.48% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $73.63, up 2.53% today, with a bullish technical signal from moving averages and strong recent earnings beats. Revenue growth is steady, reaching $10.40B in 2025, though net income margin dipped to 5.92%. Positive news includes raised 2026 profit guidance and new product launches driving investor optimism.
The outlook is positive with a consensus price target of $86.67 implying 17.7% upside, supported by analyst buy ratings. Risks include elevated P/E of 57.52 and potential tariff impacts, but operational cash flow strength and strategic collaborations provide a solid foundation for growth.
TSLY trades at $21.51, down 1.01% today, with a bearish technical signal from moving averages and mixed oscillators. The ETF generates high income through weekly distributions, but faces capped upside due to its covered call strategy on Tesla. Recent news highlights concerns over missed Tesla rallies and reduced upside capture, while distributions remain consistent, averaging around $0.28 per share recently.
Outlook is cautious due to structural limitations in capturing Tesla's gains, presenting income opportunity but significant growth risk. Investors face volatility from Tesla's performance and potential return of capital in distributions, warranting careful assessment of income versus capital appreciation goals.
Trailing returns across standard periods
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →